Companies Cryptocurrencies
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC
Exchange: NasdaqGS
IPO Date: 23/05/2019
CEO: Dr. Kevin Lee M.B.A., Ph.D.
Biotechnology Healthcare 🔗
  • BCYC
  • 54.39
  • 1563717888
    market cap
  • -3.2299995
If you bought

shares of Bicycle Therapeutics PLC (BCYC) on
You would have made
Old Price $12 Current Price $12

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. The company is headquartered in Cambridge, Cambridgeshire and currently employs 61 full-time employees. The firm is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The firm is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The firm is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.

Address: Babraham Hall Cambridge CAMBRIDGESHIRE CB22 3AT

Stay updated.